SLC2A10 Gene Arterial Tortuosity Syndrome Genetic Test in UAE

Executive Summary & Core Metrics

This next-generation sequencing (NGS) test analyzes the SLC2A10 gene for pathogenic variants causing Arterial Tortuosity Syndrome (ATS), achieving a diagnostic sensitivity of 99.9% through ISO-accredited processing. The test provides definitive molecular confirmation to guide vascular surveillance, family screening, and clinical management.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This next-generation sequencing (NGS) test analyzes the SLC2A10 gene for pathogenic variants causing Arterial Tortuosity Syndrome (ATS), a rare autosomal recessive connective tissue disorder characterized by elongated, tortuous arteries leading to stenosis, aneurysms, and dissection. The assay provides full exonic coverage with high-depth sequencing to detect single nucleotide variants, small indels, and copy number alterations, ensuring comprehensive molecular diagnosis.

Feature	Our SLC2A10 NGS Test	Conventional Sanger Sequencing
Methodology	Full gene NGS (Illumina) with VUS resolution & copy number analysis	Targeted Sanger sequencing of exonic regions only
Coverage	100% exonic & intron-exon boundaries, depth >100x	~85–90% coverage; may miss deep intronic variants
Turnaround Time	3–4 Weeks	4–6 Weeks
Clinical Interpretation	Included genetic counseling session & comprehensive report	Basic report; counseling often separate
Regulatory Compliance	Full DHA/MOHAP, ISO 9001:2015, UAE PDPL	May not include UAE-specific data privacy guarantees

Physician Insight & Safety Protocols

"As a Consultant Medical Genetics specialist, I recognize that genetic testing for rare disorders such as Arterial Tortuosity Syndrome carries profound implications for patients and families. This NGS assay delivers definitive molecular confirmation with high sensitivity, yet results must always be interpreted in the context of clinical presentation, family history, and imaging findings. A negative result does not exclude all genetic risks, and post-test genetic counseling is essential for comprehensive care planning." – Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Medication Advisory

⚠️ Important Notice: Do not discontinue or alter any prescribed medication without consulting your treating physician. Genetic test results provide diagnostic information and do not replace ongoing medical management or emergency care protocols.

Patient Exclusion Criteria

Contraindications & Precautions

This test is not intended as a standalone screening tool for asymptomatic minors or newborns without clinical suspicion; pediatric genetic testing requires prior counseling and guardian consent per UAE federal health regulations.
Pregnancy is not a contraindication; however, mandatory pre-test genetic counseling is required due to potential implications for family planning and reproductive decision-making.
Patients with known bleeding disorders or those on anticoagulant therapy must inform the phlebotomist prior to blood collection to mitigate procedural risk.

Emergency Red Flags – Seek Immediate Care

Sudden severe chest or back pain (possible aortic aneurysm or dissection).
Sudden severe headache, vision changes, or neurological deficits (cerebral artery involvement).
Acute limb pain, pallor, or absent peripheral pulses (peripheral artery thrombosis).

Patient FAQ & Clinical Guidance

1. What is the SLC2A10 gene test used for?

This test definitively diagnoses Arterial Tortuosity Syndrome by detecting pathogenic mutations in the SLC2A10 gene that cause arterial elongation, tortuosity, and vascular complications. It is ordered when a patient presents with tortuous arteries, early-onset hypertension, or a family history of sudden vascular events. The result confirms the molecular diagnosis, guides surveillance through regular vascular imaging, and enables identification of at-risk relatives.

2. How accurate is this genetic test in detecting SLC2A10 mutations?

Our NGS assay achieves 99.9% diagnostic sensitivity for SLC2A10 variants through full gene coverage, high-depth sequencing (>100x), and orthogonal validation using ISO 9001:2015 accredited protocols. The technology detects single nucleotide variants, small insertions and deletions, and copy number changes across all coding exons and splice junctions. All clinically significant findings are confirmed by an independent method prior to reporting.

3. Is home sample collection available in Dubai and Abu Dhabi?

Yes, our ISO-certified VIP Mobile Phlebotomy team provides hospital-grade home blood collection across all UAE emirates daily from 8 AM to 11 PM. Whole blood, extracted DNA, or a single drop on an FTA card can be collected at your residence. The specimen is transported in temperature-controlled, validated cold-chain containers directly to our DHA-licensed facility in Dubai Healthcare City. Appointments are scheduled via WhatsApp at +971 54 548 8731.

4. What does the turnaround time include and when will I receive my results?

The standard turnaround time is 3–4 weeks from sample receipt at our laboratory. This includes DNA extraction, library preparation, NGS sequencing on Illumina platforms, bioinformatics analysis, variant interpretation by a Consultant Medical Genetics specialist, and generation of a comprehensive clinical report. Results are delivered electronically via secure patient portal and discussed during a scheduled telephonic post-test genetic counseling session.

5. Will my health insurance cover the cost of this genetic test?

Coverage depends on your insurance provider and policy terms. Our team performs direct billing verification via WhatsApp at +971 54 548 8731 prior to sample collection. We recommend contacting your insurer to confirm pre-authorization requirements for genetic testing. The out-of-pocket price for the test is 2,800 AED.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework: This diagnostic service operates in full conformity with UAE federal health data protection and medical liability statutes. All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.

Clinical & Logistical Metadata

Test Name	SLC2A10 Gene Arterial Tortuosity Syndrome Genetic Test (NGS)
Price (AED)	2,800
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood, Extracted DNA, or FTA Card
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene Analysis with CNV Detection
ICD-10-CM Code	Q87.82
LOINC Code	81247-9
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE